Proteome and Secretome Profiling of the Melanoma-Induced Transition Toward Immune Incompetent Dendritic Cells Reveals Enhanced IDO1, Cathepsin, and Legumain Activity

Dendritic cells (DCs) are professional antigen-presenting cells endowed with the capacity to initiate strong antitumor immune responses. This function is critical for effective DC-based immunotherapies but is often hampered by tumor-derived immunosuppressive factors, as is observed for CD14<sup>+</sup>CD163<sup>+</sup> tumor-induced DC3s (ti-DC3s). ti-DC3s are increased in cancer patients where they display an immunosuppressive phenotype, accompanied by weak antigen-specific CD8 T cell-activating capacities. While tumor-derived interleukin-6, macrophage colony-stimulating factor, and prostaglandin E2 have been identified as factors inducing the transition from DC2s to ti-DC3s, a comprehensive unbiased profiling of the resulting changes in secretome and proteome has not been reported. Here, we characterized by tandem LC-MS/MS the proteomic changes in conventional DCs during their transition into CD14<sup>+</sup> ti-DC3s in vitro, using conditioned medium from the melanoma cell line BLM. This revealed 157 differentially expressed proteins, including upregulated indoleamine-2,3-dioxygenase 1 and legumain, which we confirmed to be functionally active. Next, we profiled the newly synthesized secretome in human DCs with THRONCAT metabolic labeling. We detected 17 differentially secreted proteins between DC2s and ti-DC3s, which included six cathepsins and tumor-associated transforming growth factor-β-induced protein. Cathepsin activity was validated in peripheral blood and tumor tissue of melanoma patients. We detected the highest cathepsin activity in ti-DC3s, surpassing DC2s and tumor-associated macrophages. Together, our findings represent the first characterization of the proteome and secretome of human melanoma-induced DC3s. This revealed several protein-driven protumor mechanisms active in ti-DC3s that potentially contribute to creating an immune environment favorable for tumor progression.

Authors

Institutions

Publication Details

Journal
Molecular & Cellular Proteomics
Published
2025-08-09
DOI
https://doi.org/10.1016/j.mcpro.2025.101048
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Proteome and Secretome Profiling of the Melanoma-Induced Transition Toward Immune Incompetent Dendritic Cells Reveals Enhanced IDO1, Cathepsin, and Legumain Activity

Martijn Verdoes, Iván Ramos‐Tomillero, Kimberly M. Bonger, Jelmer J. Dijkstra et al.
Molecular & Cellular Proteomics
Immunotherapy and Immune Responses
article

Proteome and Secretome Profiling of the Melanoma-Induced Transition Toward Immune Incompetent Dendritic Cells Reveals Enhanced IDO1, Cathepsin, and Legumain Activity

Martijn Verdoes, Iván Ramos‐Tomillero, Kimberly M. Bonger, Jelmer J. Dijkstra, I. Jolanda M. de Vries, Anouk M.D. Becker, Michiel Vermeulen, Bob J. Ignacio, Laura E. Edgington‐Mitchell, Floris J. van Dalen, A. Ziegler
article en

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells endowed with the capacity to initiate strong antitumor immune responses. This function is critical for effective DC-based immunotherapies but is often hampered by tumor-derived immunosuppressive factors, as is observed for CD14<sup>+</sup>CD163<sup>+</sup> tumor-induced DC3s (ti-DC3s). ti-DC3s are increased in cancer patients where they display an immunosuppressive phenotype, accompanied by weak antigen-specific CD8 T cell-activating capacities. While tumor-derived interleukin-6, macrophage colony-stimulating factor, and prostaglandin E2 have been identified as factors inducing the transition from DC2s to ti-DC3s, a comprehensive unbiased profiling of the resulting changes in secretome and proteome has not been reported. Here, we characterized by tandem LC-MS/MS the proteomic changes in conventional DCs during their transition into CD14<sup>+</sup> ti-DC3s in vitro, using conditioned medium from the melanoma cell line BLM. This revealed 157 differentially expressed proteins, including upregulated indoleamine-2,3-dioxygenase 1 and legumain, which we confirmed to be functionally active. Next, we profiled the newly synthesized secretome in human DCs with THRONCAT metabolic labeling. We detected 17 differentially secreted proteins between DC2s and ti-DC3s, which included six cathepsins and tumor-associated transforming growth factor-β-induced protein. Cathepsin activity was validated in peripheral blood and tumor tissue of melanoma patients. We detected the highest cathepsin activity in ti-DC3s, surpassing DC2s and tumor-associated macrophages. Together, our findings represent the first characterization of the proteome and secretome of human melanoma-induced DC3s. This revealed several protein-driven protumor mechanisms active in ti-DC3s that potentially contribute to creating an immune environment favorable for tumor progression.

Molecular & Cellular ProteomicsVol. 24(9)
Radboud University Nijmegen (NL), The University of Melbourne (AU), Radboud University Medical Center (NL), Synthon (Netherlands) (NL), Radboud Institute for Molecular Life Sciences (NL), Oncode Institute (NL)
European Commission, Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Openalex Percentile: Top 78%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.